Chris Garabedian is an industry pioneer with over two decades of experience guiding and building early stage biopharma companies to ensure development success. In June of 2016, Chris founded Xontogeny to support multiple promising technologies from early development through clinical proof of concept and formed a partnership with Perceptive Advisors in 2017 to establish the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Chris helps source, identify and fund venture opportunities as part of the Xontogeny portfolio and beyond. Chris has a broad base of experience and a track record of success across his career in the pharma and biotech industries, including at two of the most successful biopharma companies in the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics , leading the development of the company’s Duchenne Muscular Dystrophy program and overseeing the turnaround of the company into a commercial stage leader in the genetic technology space. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group.